{
    "2021-10-25": [
        [
            {
                "time": "",
                "original_text": "康泰生物：全球首款双载体13价肺炎疫苗获批上市",
                "features": {
                    "keywords": [
                        "康泰生物",
                        "双载体",
                        "13价肺炎疫苗",
                        "获批上市"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "山西证券：给予康泰生物增持评级",
                "features": {
                    "keywords": [
                        "山西证券",
                        "康泰生物",
                        "增持评级"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "山西证券维持康泰生物增持评级：新冠疫苗带动三季度业绩，13价肺炎疫苗获批准上市",
                "features": {
                    "keywords": [
                        "山西证券",
                        "康泰生物",
                        "新冠疫苗",
                        "三季度业绩",
                        "13价肺炎疫苗",
                        "获批上市"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "太平洋维持康泰生物买入评级：Q3业绩高速增长，重磅品种13价肺炎疫苗获批准，放量可期",
                "features": {
                    "keywords": [
                        "太平洋",
                        "康泰生物",
                        "Q3业绩",
                        "高速增长",
                        "13价肺炎疫苗",
                        "放量可期"
                    ],
                    "sentiment_score": 0.95,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "德邦证券：给予康泰生物买入评级，目标价位158.2元",
                "features": {
                    "keywords": [
                        "德邦证券",
                        "康泰生物",
                        "买入评级",
                        "目标价位"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "康泰生物前三季净利润大增139% 研发投入“节节攀升”",
                "features": {
                    "keywords": [
                        "康泰生物",
                        "前三季",
                        "净利润",
                        "大增139%",
                        "研发投入",
                        "节节攀升"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "钛媒体科股早知道：“双11”预售正式启动，头部网红单日销售额超100亿元；全国累计接种新冠疫苗超22亿剂次",
                "features": {
                    "keywords": [
                        "双11",
                        "预售",
                        "头部网红",
                        "销售额",
                        "新冠疫苗",
                        "接种",
                        "22亿剂次"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "消费",
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}